The efficacy of switching from sulfonyl urea to repaglinide on glycemic control in elderly patients with type 2 diabetes

The efficacy of switching from sulfonyl urea to repaglinide on glycemic control in elderly patients with type 2 diabetes - The effect of repaglinide on glycemic control in elderly patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022531

Enrollment

Registered

2016-05-30

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Keeping sulfonylureas Switching from sulfonylureas to repaglinide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Elderly patients with type 2 diabetes who have been taking sulfonylurea (Glimepiride/ Gliclazide/ Glibenclamide equal to or more than 1 mg /40 mg/1.25 mg per day ). 2)Age: 60 to 90 years old 3) BMI< 25 kg/m^2 4) HbA1c 7.0 to 9.0 % 5) Written informed consent

Exclusion criteria

Exclusion criteria: 1)patients with hypersensitivity to repaglinide 2) patients with severe liver dysfunction 3)patients who thought to be inappropriate to enter this study for some reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Secondary

Measure	Time frame
Weight, BMI Fasting plasma glucose, glicolalbumin,and 1.5-AG Frequency of hypoglycemia Blood pressure Lipid metabolism Liver function Complete blood count, renal function, electrolyte Dose of Sulfonylurea before and during clinical trial Urine test Questionnaires for adherence to drug medication	—

Countries

Japan

Contacts

Public ContactKazuno Omori

Hokkaido University Hospital Department of Internal Medicine II

kazunoko@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026